Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2012

01.07.2012 | Short Communication

The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response

verfasst von: Trevor G. Glaros, Luke H. Stockwin, Michael E. Mullendore, Brian Smith, Bethanie L. Morrison, Dianne L. Newton

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To establish whether NSC80467, a novel fused naphthquinone imidazolium, has a similar spectrum of activity to the well-characterized “survivin suppressant” YM155 and to extend mechanistic studies for this structural class of agent.

Methods

NSC80467 and YM155 were analyzed in parallel using assays measuring viability, survivin suppression, inhibition of DNA/RNA/protein synthesis and the cellular response to DNA damage.

Results

GI50 values generated for both compounds in the NCI-60 screen yielded a correlation coefficient of 0.748, suggesting significant concordance. Both agents were also shown to inhibit protein expression of survivin [BIRC5]. COMPARE analysis identified DNA damaging agents chromomycin A3 and bisantrene HCl and one DNA-directed inhibitor of transcription, actinomycin D, as correlating with the activity of NSC80467 and YM155. Furthermore, both agents were shown to preferentially inhibit DNA, over RNA and protein synthesis. Thus, the ability of NSC80467 and YM155 to induce a DNA damage response was examined further. Treatment of PC3 cells with either agent resulted in dose-dependent induction of γH2AX and pKAP1, two markers of DNA damage. The concentrations of agent required to stimulate γH2AX were considerably lower than those required to inhibit survivin, implicating DNA damage as an initiating event. The DNA damage response was then confirmed in a panel of cell lines treated with NSC80467 or YM155, suggesting that γH2AX and pKAP1 have potential as response biomarkers.

Conclusions

These data provide the first evidence that NSC80467 and YM155 are DNA damaging agents where suppression of survivin is a secondary event, likely a consequence of transcriptional repression.
Literatur
1.
Zurück zum Zitat Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B (1996) Clinical reversal of multidrug resistance. Oncologist 1(4):269–275PubMed Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B (1996) Clinical reversal of multidrug resistance. Oncologist 1(4):269–275PubMed
2.
Zurück zum Zitat Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 95(5):2205–2214. doi:10.1172/JCI117910 PubMedCrossRef Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 95(5):2205–2214. doi:10.​1172/​JCI117910 PubMedCrossRef
3.
Zurück zum Zitat Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M, Sasamata M (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67(17):8014–8021. doi:10.1158/0008-5472.CAN-07-1343 PubMedCrossRef Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M, Sasamata M (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67(17):8014–8021. doi:10.​1158/​0008-5472.​CAN-07-1343 PubMedCrossRef
4.
Zurück zum Zitat Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S (2011) A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer. doi:10.1002/cncr.26510 PubMed Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S (2011) A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer. doi:10.​1002/​cncr.​26510 PubMed
5.
Zurück zum Zitat Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS (2011) A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. doi:10.1093/annonc/mdr353 PubMed Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS (2011) A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. doi:10.​1093/​annonc/​mdr353 PubMed
6.
Zurück zum Zitat Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R (2011) A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 29(1):161–166. doi:10.1007/s10637-009-9333-6 PubMedCrossRef Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R (2011) A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 29(1):161–166. doi:10.​1007/​s10637-009-9333-6 PubMedCrossRef
7.
Zurück zum Zitat Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27(27):4481–4486. doi:10.1200/JCO.2008.21.1862 PubMedCrossRef Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27(27):4481–4486. doi:10.​1200/​JCO.​2008.​21.​1862 PubMedCrossRef
9.
Zurück zum Zitat Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81(14):1088–1092PubMedCrossRef Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81(14):1088–1092PubMedCrossRef
10.
Zurück zum Zitat Stockwin LH, Yu SX, Stotler H, Hollingshead MG, Newton DL (2009) ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer 9:63. doi:10.1186/1471-2407-9-63 PubMedCrossRef Stockwin LH, Yu SX, Stotler H, Hollingshead MG, Newton DL (2009) ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer 9:63. doi:10.​1186/​1471-2407-9-63 PubMedCrossRef
11.
Zurück zum Zitat Chatterjee S, Zaman K, Ryu H, Conforto A, Ratan RR (2001) Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol 49(3):345–354PubMedCrossRef Chatterjee S, Zaman K, Ryu H, Conforto A, Ratan RR (2001) Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol 49(3):345–354PubMedCrossRef
12.
Zurück zum Zitat Foye WO, Karnik PS, Sengupta SK (1986) DNA-binding abilities of bisguanylhydrazones of anthracene-9,10-dicarboxaldehyde. Anticancer Drug Des 1(2):65–71PubMed Foye WO, Karnik PS, Sengupta SK (1986) DNA-binding abilities of bisguanylhydrazones of anthracene-9,10-dicarboxaldehyde. Anticancer Drug Des 1(2):65–71PubMed
13.
Zurück zum Zitat Sobell HM (1985) Actinomycin and DNA transcription. Proc Natl Acad Sci USA 82(16):5328–5331PubMedCrossRef Sobell HM (1985) Actinomycin and DNA transcription. Proc Natl Acad Sci USA 82(16):5328–5331PubMedCrossRef
15.
Zurück zum Zitat Li X, Lee YK, Jeng JC, Yen Y, Schultz DC, Shih HM, Ann DK (2007) Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J Biol Chem 282(50):36177–36189. doi:10.1074/jbc.M706912200 PubMedCrossRef Li X, Lee YK, Jeng JC, Yen Y, Schultz DC, Shih HM, Ann DK (2007) Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J Biol Chem 282(50):36177–36189. doi:10.​1074/​jbc.​M706912200 PubMedCrossRef
Metadaten
Titel
The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response
verfasst von
Trevor G. Glaros
Luke H. Stockwin
Michael E. Mullendore
Brian Smith
Bethanie L. Morrison
Dianne L. Newton
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-012-1868-0

Weitere Artikel der Ausgabe 1/2012

Cancer Chemotherapy and Pharmacology 1/2012 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.